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Panel: Research in context 
Evidence before this study 
 Semaglutide is a glucagon-like peptide-1 (GLP-1) analogue in development for the 
treatment of type 2 diabetes (T2D), with a pharmacokinetic profile suitable for once-
weekly dosing.  
 It is structurally similar to liraglutide, an approved once-daily GLP-1 analogue, with 
modifications to extend its half-life and dosing profile.  
 The design of this trial was based on preclinical safety and pharmacology findings, and 
the clinical phase 1 and 2 trials, which have supported further assessment of 
semaglutide in a phase 3 clinical trial programme. 
 Results from the phase 2 dose-finding trial and one of the phase 1 semaglutide trials, 
indicate that an adjusted dose-escalation regimen is likely to offer a more acceptable 
gastrointestinal (GI) tolerability profile, whilst maintaining efficacy, than starting at the 
final dose. 
Added value of this study 
 This phase 3a trial demonstrates that semaglutide combines substantial lowering of 
HbA1c with substantial weight loss, compared with basal insulin glargine as a reference 
active comparator. The safety profile of gradually titrated semaglutide appears to be 
similar to currently available GLP-1 receptor agonists (GLP-1RAs), consisting primarily of 
GI events, with a lower risk of hypoglycaemia compared with insulin glargine. 
Implications of all the available evidence  
 Semaglutide, administered once weekly, appears to be a valuable treatment for patients 
with T2D inadequately controlled on metformin, with or without sulphonylureas, as it 
exhibits both significant improvements in glycaemic control and an extent of weight loss 
that appears greater than has been reported for other GLP-1RAs. A combination of 
glucose-lowering effect and weight loss is particularly important in addressing the 
underlying pathophysiology of T2D. Semaglutide has an acceptable safety profile, which 
is similar to that of other GLP-1RAs.   
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Summary (max 300 words, currently 254 words including funding statement) 
Background 
Despite a broad range of pharmacological options for type 2 diabetes (T2D) treatment, 
optimal glycaemic control remains challenging for many patients and new therapies remain 
necessary. Semaglutide is a glucagon-like peptide-1 (GLP-1) analogue in phase 3a 
development for T2D. 
Methods 
SUSTAIN 4 (ClinicalTrials.gov: NCT02128932) was a randomised, phase 3a, open-label trial 
assessing the non-inferiority of once-weekly 0·5 and 1·0 mg semaglutide compared with 
once-daily insulin glargine in insulin-naïve subjects with T2D inadequately controlled with 
metformin, with or without sulphonylureas. Primary endpoint was change in HbA1c from 
baseline at week 30. 
Findings 
The trial was conducted from 4 August 2014 to 3 September 2015. In total, 1089 adults 
were randomised. From a mean baseline HbA1c of 8·2% to week 30, 0·5 and 1·0 mg 
semaglutide  achieved superior reductions of 1·2% and 1·6%, versus 0·8% with insulin 
glargine; estimated treatment difference (ETD) [95% CI] –0·38% [–0·52, –0·24] and –
0·81% [–0·96, –0·67], both p<0·0001. Semaglutide 0·5 and 1·0 mg achieved superior 
weight loss of 3·5 kg and 5·2 kg versus 1·2 kg gain with insulin glargine (ETD –4·62 [–5·27; 
–3·96] and –6·33 [–6·99; –5·67] kg, both p<0·0001). Mean daily insulin glargine dose at 
week 30 was 29·2 IU/day. Severe or blood glucose-confirmed hypoglycaemia was reported 
by 4·4% and 5·6% of subjects treated with semaglutide 0.5 and 1·0 mg versus 10·6% with 
insulin glargine (p=0·0021 and 0·0202)). The proportion of subjects reporting severe 
hypoglycaemia was 0.6%, 1.4% and 1.4%, respectively. Proportions of subjects 
discontinuing treatment prematurely due to adverse events (mainly gastrointestinal) were 
5·5%, 7·5% and 1·1%, respectively. 
Interpretation 
Semaglutide resulted in superior HbA1c and weight reduction with fewer hypoglycaemic 
episodes, compared with insulin glargine. Semaglutide was well-tolerated, with a similar 
safety profile to other GLP-1RAs.  
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Introduction 
Type 2 diabetes (T2D) is a complex disorder that requires individualised treatment 
strategies. Due to the progressive nature of T2D, most patients will require treatment 
intensification, which can be in the form of additional antihyperglycaemic agents either as 
an oral or an injectable therapy.1 Currently, the most commonly used injectable treatments 
for patients failing to meet targets on oral therapy are basal insulins or glucagon-like 
peptide 1 receptor agonists (GLP-1RAs).1 
Basal insulin, while effective in controlling hyperglycaemia for many patients,2,3 is 
associated with adverse effects such as hypoglycaemia and weight gain.4 By contrast, GLP-
1RAs stimulate insulin secretion and inhibit the release of glucagon from pancreatic islets in 
a glucose-dependent manner,5 resulting in effective glucose lowering that is comparable to 
basal insulin therapy while limiting hypoglycaemia.6 GLP-1RAs have also been shown to 
reduce body weight.6 While GLP-1RAs were initially used once- or twice-daily, recent efforts 
have focused on the development of once-weekly GLP-1RAs, with the potential to improve 
adherence and quality of life for patients.6,7 
Semaglutide, a GLP-1 analogue currently in development, is structurally similar to 
liraglutide, an approved once-daily GLP-1 analogue. Structural modifications of the 
semaglutide molecule include amino acid substitutions at position 8 (alanine to -
aminoisobutyric acid) and position 34 (lysine to arginine), and acylation of the lysine in 
position 26 with a spacer and C-18 fatty diacid chain.8 The substitution at position 8 renders 
semaglutide less susceptible to degradation by dipeptidyl peptidase-4 (DPP-4), while the 
lysine acylation improves binding to albumin.8 These modifications extend the half-life of 
semaglutide to approximately 1 week,8 enabling once-weekly administration.9,10  
Here, we report the findings from the Semaglutide Unabated Sustainability in Treatment of 
Type 2 Diabetes 4 (SUSTAIN 4) phase 3a trial, which aimed to evaluate the efficacy, safety 
and tolerability of subcutaneous (s.c.) semaglutide at doses of 0·5 mg and 1·0 mg once 
weekly compared with once-daily insulin glargine titrated to fasting glucose target. The trial 
cohort were insulin-naïve subjects with T2D, with inadequate glycaemic control on 
metformin, with or without sulphonylureas. 
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Methods 
Study design 
SUSTAIN 4 was a phase 3a, randomised, open-label, active-controlled, parallel-group, 
multicentre, multinational, three-armed trial (ClinicalTrials.gov no. NCT02128932). The trial 
was conducted at 196 participating sites located in Argentina, Croatia, France, Germany, 
India, Macedonia, Mexico, the Netherlands, Romania, Slovakia, Slovenia, South Africa, UK 
and the USA. This trial was conducted in compliance with the International Conference on 
Harmonisation Good Clinical Practice guidelines and the Declaration of Helsinki. This analysis 
is based on the completed trial after 30 weeks, and no interim analyses were planned.  
Participants 
Insulin naïve subjects who were ≥18 years old, diagnosed with T2D and on stable treatment 
with metformin alone or in combination with sulphonylureas 90 days prior to screening were 
included in the trial. Eligible subjects had an HbA1c value of 7·0–10·0% (53–86 mmol/mol). 
Key exclusion criteria included a history of chronic or idiopathic acute pancreatitis, a 
screening calcitonin value of ≥50 ng/L, any personal or family history of medullary thyroid 
carcinoma or multiple endocrine neoplasia syndrome type 2, severely impaired renal 
function (estimated glomerular filtration rate [eGFR] <30 ml/min/1·73 m2), heart failure 
(New York Heart Association class IV) or any acute coronary or cerebrovascular events 
within the last 90 days. Subjects with known proliferative retinopathy or maculopathy 
requiring acute treatment were also excluded, and any cases of retinopathy identified in the 
trial were likely to be new cases. Retinopathy was not explicitly screened for during the trial 
itself. Full eligibility criteria are included in Supplementary Material 1. Written informed 
consent was obtained from all participants. The protocol was approved by all local ethics 
committees and institutional review boards. 
Randomisation and masking 
Subjects were randomly assigned with a 1:1:1 ratio to receive once-weekly s.c. semaglutide 
(0·5 mg or 1·0 mg) or once-daily insulin glargine using an interactive voice/web response 
system. Both investigators and subjects were unblinded, apart from members of the 
external event adjudication committee (EAC). 
Procedures 
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Following a 2-week screening period, subjects received once-weekly s.c. semaglutide 
(0·5 mg or 1·0 mg; Novo Nordisk A/S, Bagsværd, Denmark) or once-daily insulin glargine 
(Lantus® U100, Sanofi, Gentilly, France) for 30 weeks, followed by a 5-week follow-up 
period. Subjects who stopped treatment prematurely were encouraged to remain in the trial 
and complete follow up. Semaglutide dosing was selected based on the findings of the 
phase 2 dose-finding trial,11 and subjects followed a fixed dose-escalation regimen. In those 
allocated to receive semaglutide 0·5 mg, this dose was reached after 4 weeks of once-
weekly 0·25 mg semaglutide. In the semaglutide 1·0 mg arm, this dose was reached after 
4 weeks of once-weekly 0·25 mg semaglutide, followed by 4 weeks of once-weekly 0·5 mg 
semaglutide. 
Subjects in the insulin glargine arm started on a dose of 10 IU once daily. Protocol 
instructions were to titrate the insulin dose weekly to a pre-breakfast self-measured plasma 
glucose (SMPG) target of 4·0–5·5 mmol/L (72–99 mg/dL) (Supplementary Material 2). 
Titration was according to the lowest value of each subject’s fasting 1-point profile SMPG 
levels 3 days prior to visits or phone contacts. Injections were administered in the thigh, 
abdomen or upper arm. For semaglutide, injections could be done at any time of the day, 
but on the same day each week. In all treatment groups, prior background metformin 
and/or sulphonylurea treatment was continued throughout the trial.  
Subjects with unacceptable hyperglycaemia (defined as any fasting SMPG measurement 
>15·0 mmol/L [270 mg/dL] from randomisation to end of week 5, 13·3 mmol/L [240 
mg/dL] from week 6 to end of week 11 or 11·1 mmol/L [200 mg/dL] after week 12) were to 
be offered rescue treatment (intensification of existing background medication and/or 
initiation of new medication, preferably excluding GLP-1RAs, DPP-4 inhibitors or amylin 
analogues) as add-on to their randomised treatment  at the discretion of the investigator, in 
accordance with current American Diabetes Association (ADA)/European Association for the 
Study of Diabetes (EASD) treatment recommendations.1 
Outcomes 
The primary endpoint was change in HbA1c from baseline to week 30 (end of treatment). 
The confirmatory secondary endpoint was change in body weight from baseline to week 30. 
Other secondary efficacy endpoints included proportion of subjects who achieved HbA1c 
<7·0% (53 mmol/mol12) or ≤6·5% (48 mmol/mol13) by end of treatment, proportion of 
subjects achieving HbA1c <7·0% (53 mmol/mol) without severe (by ADA classification 
[event requiring assistance of another person to actively administer carbohydrates, 
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glucagon, or take other corrective actions]14) or blood-glucose (BG)-confirmed symptomatic 
hypoglycaemia (plasma glucose ≤3·1 mmol/L or 56 mg/dL) and no weight gain, change 
from baseline in fasting plasma glucose (FPG), mean 8-point SMPG profiles and postprandial 
increment, proportion of subjects who achieved ≥5% and ≥10% weight loss by end of 
treatment , change from baseline in body mass index (BMI), waist circumference, fasting 
blood lipids, systolic and diastolic blood pressure (BP), plasminogen activator inhibitor-1 
[PAI-1], C-reactive protein [CRP] and patient-reported outcomes (PROs; Short Form [SF]-
36v2™ health survey and Diabetes Treatment Satisfaction Questionnaire [DTSQ]). 
Safety endpoints included the number of treatment-emergent adverse events (AEs), the 
number of treatment-emergent severe or BG-confirmed symptomatic hypoglycaemic 
episodes during exposure and pulse rate. Other safety measurements were change in 
laboratory parameters (haematology, biochemistry, calcitonin, urinalysis, and urinary 
albumin-to-creatinine ratio) and examinations (ECG and physical examination) at week 30, 
the occurrence and level of anti-semaglutide antibodies, and semaglutide pharmacokinetics 
(to be included in a future population pharmacokinetic analyses across semaglutide phase 
3a trials). 
The need for a Data Monitoring Committee (DMC) was considered by Novo Nordisk in 
accordance with the guidance given by Food and Drug Administration and the European 
Medicines Agency and it was decided that the trial did not meet the need for a DMC. 
An independent EAC validated predefined events in a blinded manner (Supplementary 
Material 3). 
Statistical analysis 
The trial was powered to the primary objective (change in HbA1c level at 30 weeks) of 
demonstrating non-inferiority for both doses of semaglutide, separately tested against 
insulin glargine, under the following assumptions: no treatment difference; a non-inferiority 
margin of 0.3%; 1:1:1 randomisation; standard deviation of 1.1%; one-sided 0.025 
significance level; and a 30% dropout rate. Based on this sample size of 1047 subjects was 
specified, ensuring at least 90% power for each of the HbA1c non-inferiority tests. Further, 
this ensured 99% power to detect a difference between semaglutide 1.0 mg vs insulin 
glargine of 1.5 kg in change in body weight, with a standard deviation of 4 kg. 
Conservatively assuming independence between the two endpoints, the joint power is 80%.  
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To preserve the overall type 1 error rate, a pre-specified hierarchical testing was performed 
(Supplementary Figure 1): non-inferiority in change in HbA1c for semaglutide 1.0 mg vs 
insulin glargine; superiority in change in body weight for semaglutide 1.0 mg vs insulin 
glargine; non-inferiority in change in HbA1c for semaglutide 0.5 mg vs insulin glargine; 
superiority in change in HbA1c for semaglutide 1.0 mg vs insulin glargine; superiority in 
change in body weight for semaglutide 0.5 mg vs insulin glargine; and superiority in change 
in HbA1c for semaglutide 0.5 mg vs insulin glargine. Superiority for either change in HbA1c or 
in body weight was considered established if the upper limit of the 2-sided 95% confidence 
interval for the estimated difference was below 0% or 0 kg, respectively.  
The evaluation of efficacy was based on a modified intention to treat (mITT), comprising all 
randomised subjects who were exposed to at least one dose of trial product, as specified in 
the trial protocol; the evaluation used data collected before the initiation of any rescue 
medication or before premature treatment discontinuation. Safety was evaluated based on 
the same set of subjects. For safety, only data collected before premature treatment 
discontinuation with an ascertainment window of 42 days were used to define treatment-
emergent adverse events. Supportive analyses using all data collected during the trial were 
performed for both efficacy and safety. 
Analysis methods for HbA1c and body weight and other continuous endpoints assessed over 
time included a mixed model for repeated measurements (MMRM), with factors for 
treatment, country, stratum (metformin ± sulphonylurea) and baseline value, all nested 
within visits. An unstructured covariance matrix was assumed for measurements within the 
same subject. Outcomes evaluating the secondary HbA1c and body weight targets were 
analysed using logistic regression. All p-values were two-sided test of the null hypothesis of 
no treatment difference. All statistical testing was done at the 0.05 significance level. 
The robustness of the analyses of HbA1c and body weight was assessed by handling missing 
data in various ways, including a comparator-based multiple imputation model where 
missing data points were imputed based on observed data in the insulin glargine arm. 
Sensitivity analyses also included an MMRM analysis on the mITT population using all data, 
regardless of whether obtained while the subjects had discontinued the trial product and/or 
whether the subject had been administered rescue medication (supplementary materials).  
Role of the funding source 
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The sponsor designed the trial and developed the protocol in consultation with the first and 
last authors. The sponsor provided logistical support during the trial and obtained the data. 
The authors interpreted the data and wrote the report together with medical writing services 
provided by the sponsor. The corresponding author had full access to all data and had final 
responsibility for the decision to submit for publication. 
Results 
The trial was conducted from 4 August 2014 to 3 September 2015, with subjects recruited 
between 4 Aug 2014 and 16 Dec 2014. In total, 1089 adults with T2D were randomised to 
one of the semaglutide doses or insulin glargine, of whom 1082 (99%) were exposed to trial 
medication (Figure 1). In all, 1020 (94%) of randomised subjects completed the trial and 
952 (88%) completed treatment. The proportion of subjects completing randomised 
treatment without the need for rescue medication was 82·6% with semaglutide 0·5 mg, 
82·2% with semaglutide 1·0 mg, and 91·4% with insulin glargine. A total of 49 (13·5%) 
subjects in the semaglutide 0·5 mg group discontinued treatment prematurely, compared 
with 55 (15·3%) in the semaglutide 1·0 mg group. Fewer subjects (26 [7·2%]) discontinued 
treatment prematurely in the insulin glargine group. Most treatment discontinuations were 
due to AEs (mostly GI with semaglutide and of other causes with insulin glargine). Baseline 
characteristics were similar between all groups. Overall, 52% of subjects were on 
sulphonylureas (Table 1).  
Mean HbA1c (baseline 8·2%, SD 0·89%) decreased significantly over time in all three 
groups, with most of the decrease occurring by week 12 (Figure 2A). By week 30, mean 
HbA1c decreased significantly with semaglutide 0·5 mg and 1·0 mg by 1·2% and 1·6%, 
respectively, versus 0·8% in the insulin glargine group; estimated treatment differences 
(ETD) versus insulin glargine (95% confidence interval [CI]) –0·38% (–0·52; –0·24) and –
0·81% (–0·96 to –0·67); p<0.0001 for both; Figure 2B, Table 2). The mean insulin glargine 
dose at end of treatment was 29·2 IU/day. Results from the sensitivity analyses for HbA1c 
confirm the primary analysis results and are provided in Supplementary Figure 1a. 
HbA1c <7% (<53 mmol/mol) was achieved by 57% and 73% of 0·5 mg and 1·0 mg 
semaglutide treated subjects, respectively, versus 38% in the insulin glargine group 
(p<0·0001; Table 2). HbA1c ≤6·5% (≤48 mmol/mol) was achieved by 37% and 54% of 0.5 
mg and 1.0 mg semaglutide-treated subjects, respectively, versus 18% in the insulin 
glargine group (p<0·0001 for both; Table 2). 
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The number of subjects achieving HbA1c <7% without severe or BG-confirmed symptomatic 
hypoglycaemia and without weight gain was 169 (47% of subjects) in the semaglutide 0·5 
mg group and 231 (64%) in the semaglutide 1·0 mg group versus 56 (16%) in the insulin 
glargine group (p<0·0001 for both).  
Mean FPG was reduced with all three groups (Table 2, Figure 2C–D). In the semaglutide 
0·5 mg and insulin glargine groups, FPG decreased by a comparable amount (ETD 
0·08 mmol/L [p=0·6243]) while, in the semaglutide 1.0 mg group, FPG decreased 
significantly more than with insulin glargine (ETD –0·61 mmol/L [p=0·0002]).  
Mean 8-point SMPG was also reduced in all three groups. The decrease from baseline in the 
semaglutide 0·5 mg and insulin glargine groups was similar (ETD –0·04 mmol/L 
[p=0·7816]), while in the semaglutide 1·0 mg group, the decrease was significantly greater 
than for insulin glargine (ETD –0·57 mmol/L [p<0·0001]; Figure 2G and Table 2). Mean 8-
point SMPG postprandial increments decreased in the semaglutide 0·5 mg and 1·0 mg 
groups significantly more than with insulin glargine (ETD –0·39 [p=0·0029] and –0·65 
[p<0·0001], respectively; Table 2).  
At week 30, mean body weight decreased significantly  with semaglutide 0.5 mg and 1.0 mg 
by 3·5 kg and 5·2 kg, respectively, versus an increase of 1·2 kg in the insulin glargine group 
(ETD [95% CI] –4·62 kg [–5·27; –3·96] and –6·33 kg [–6·99; –5·67], respectively; 
p<0·0001 for both; Figure 2E–F, Table 2). A body weight reduction of ≥5% was observed in 
37% and 51% of 0·5 mg and 1·0 mg semaglutide-treated subjects, respectively, versus 4% 
in the insulin glargine group (p<0·0001 for both; Table 2). A body weight reduction of 
≥10% was observed in 7% and 16% of 0·5 mg and 1·0 mg semaglutide-treated subjects, 
respectively, versus 1% in the insulin glargine group (p=0.002 and p<0.0001, respectively, 
Table 2). Results from the sensitivity analyses for body weight confirmed this finding and 
are shown in Supplementary Figure 1b. BMI and waist circumference were significantly 
reduced with both doses of semaglutide compared with insulin glargine (Table 2). 
Changes in lipid levels, and in levels of CRP and PAI-1, are detaild in supplementary tables 1 
and 2.  
Both systolic BP and diastolic BP decreased in the three treatment groups (Table 2). Systolic 
BP decreased to a significantly greater extent (by –1·7 mmHg) in the semaglutide 0·5 mg 
and 1·0 mg groups compared with the insulin glargine group (ETD –2·97 mmHg and –3·50 
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mmHg, respectively). Corresponding changes in diastolic BP were smaller and were not 
significant in either case (ETD 0·06 mmHg and 0·45 mmHg, respectively).  
Pulse increased significantly with semaglutide 0·5 mg and 1·0 mg by 2·3 bpm and 3·1 bpm, 
respectively, versus a <0·1 bpm decrease with insulin glargine (Table 2). Overall treatment 
satisfaction (as per DTSQ; baseline 26·9 ± 7·01) improved by 4·6, 5·6 and 3·7 points with 
semaglutide 0·5 mg, semaglutide 1·0 mg and insulin glargine, respectively (ETD 0·87 
[p=0·0254] and 1·38 [p=0·0005]; Supplementary Figure 2). The frequency with which 
subjects felt that their blood sugars had been unacceptably high was reduced to a 
significantly greater extent in the semaglutide 0·5 mg and 1·0 mg groups, compared with 
insulin glargine (ETD –0·44 [p=0·0011] and –0·71 [p<0·0001]). Results from the SF-36v2™ 
questionnaire were significantly improved with semaglutide 1·0 mg compared with insulin 
glargine in two of the eight domains (Supplementary Figure 3): role-emotional (ETD 1·67, 
p=0·0257) and general health (ETD 1·15, p=0·0291). 
The proportion of subjects reporting treatment-emergent AEs was 69·9%, 73·3% and 
65·3% with semaglutide 0·5, 1·0 mg and insulin glargine, respectively, with 6·1%, 4·7% 
and 5·0% of subjects reporting serious AEs (Table 3).  
AEs with fatal outcome were reported in four subjects treated with 0·5 mg semaglutide 
(3 subjects with cardiovascular death [EAC-confirmed] and 1 pancreatic carcinoma 
[detected 149 days into the trial]) and 2 subjects treated with insulin glargine (2 subjects 
with cardiovascular death [EAC-confirmed]), with none in the semaglutide 1.0 mg arm. 
Diabetic retinopathy was reported by 1 subject (0.3%) each in the semaglutide 0.5 mg and 
insulin glargine groups and none in the semaglutide 1.0 mg group. Only 1 subject (0.3%) in 
the insulin glargine group reported proliferative retinopathy. 
The proportion of subjects discontinuing treatment prematurely due to AEs was 5·5% for 
the semaglutide 0·5 mg group and 7·5% for the 1·0 mg group; both were higher than 
insulin glargine (1·1%; Supplementary Figure 6). The most frequent AEs (Table 3) and the 
majority of AEs leading to premature treatment discontinuation in the semaglutide groups 
were gastrointestinal (GI) events. In the semaglutide groups, GI events were mainly mild or 
moderate in severity and diminished in frequency over time (Figure 3). Nausea was 
reported in 21·3%, 22·2% and 3·6% of subjects in the semaglutide 0·5 mg, 1·0 mg and 
insulin glargine groups, respectively. Vomiting was reported in 6·6%, 10·3% and 3·1%, and 
diarrhoea was reported in 16·3%, 19·2% and 4·4% of subjects in the semaglutide 0·5 mg, 
1·0 mg and insulin glargine groups, respectively. Compared with insulin glargine, lipase and 
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amylase levels both increased significantly more in both semaglutide groups compared to 
glargine, without a clear dose-dependent effect (Supplementary Figure 7). 
Severe or BG-confirmed hypoglycaemia was reported by 4·4% of subjects receiving 0·5 mg 
semaglutide and 5·6% of those receiving 1·0 mg semaglutide, compared with 10·6% of 
those receiving insulin glargine (p<0·0001 for both). Most of these episodes were reported 
in subjects receiving sulphonylurea as background medication; 8.1%, 8.6% and 18.1% of 
these subjects experienced severe or BG-confirmed hypoglycaemia compared with 0.6%, 
2.3% and 2.3% of those not receiving sulphonylurea as background medication. The 
proportion of subjects reporting severe hypoglycaemia was 0.6%, 1.4% and 1.4%, 
respectively. Nocturnal severe or BG-confirmed hypoglycaemia was reported by 1·1% of 
subjects receiving 0·5 mg semaglutide and 0·8% of those receiving 1·0 mg semaglutide, 
compared with 2·2% of subjects receiving insulin glargine. 
A total of three cases of cholelithiasis were reported (none classified as severe); one in the 
semaglutide 0.5 mg group and two in the semaglutide 1.0 mg group. In one of the subjects 
receiving semaglutide 0.5 mg, this was categorised as a serious AE (SAE). Two pancreatic 
AEs were reported, both in the semaglutide 0·5 mg group, and were adjudicated as mild, 
acute pancreatitis. Both subjects discontinued treatment prematurely and symptoms 
resolved after treatment discontinuation. 
EAC-confirmed neoplasms were reported by 8 subjects treated with semaglutide 0.5 mg, 2 
subjects on semaglutide 1.0 mg and 3 subjects on insulin glargine. These included 4 
subjects with malignant neoplasms (skin, nasopharyngeal, pancreatic and renal/adrenal) in 
the semaglutide 0.5 mg group, none in the semaglutide 1.0 mg group and one in the insulin 
glargine group. Calcitonin levels were comparable between groups with no apparent change 
during the trial. A decline in eGFR was observed in all three arms during the first 12 weeks 
of treatment, and then stayed stable over remaining duration of the trial (Supplementary 
Figure 4). EAC-confirmed cardiovascular adverse events are detailed in supplementary table 
3. 
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Discussion 
In this multicentre, randomised, phase 3a trial, both semaglutide 0·5 mg and 1·0 mg 
achieved superiority over insulin glargine in improving overall glycaemic control and 
inducing body weight loss in subjects with T2D after 30 weeks of treatment, with non-
inferiority as the primary analysis.  
A greater proportion of subjects in both the semaglutide 0·5 mg and 1·0 mg groups 
achieved HbA1c targets set by the ADA/EASD and the American Association of Clinical 
Endocrinologists compared with those in the insulin glargine group. This observation 
compares favourably with previous findings for liraglutide,15 and for other once-weekly GLP-
1RAs such as dulaglutide and exenatide,16,17 compared with insulin glargine. Furthermore, 
semaglutide led to substantial weight loss (3·5–5·2 kg versus baseline), with more subjects 
on semaglutide 0·5 mg and 1·0 mg experiencing clinically significant (≥5%) weight 
reduction, compared with insulin glargine. Trials with other GLP-1RAs have reported 
reductions of –0·4–2·5 kg.18-21 The weight reduction achieved with semaglutide compared 
with insulin glargine (4.6–6.3 kg) also compared favourably to that reported with other 
long-acting GLP-1RAs (2.6–4.0 kg).16,17,22 However, comparisons of these trials should be 
made with caution due to the differences in study design and patient populations between 
individual trials.   
Consistent with these findings, the secondary composite endpoint (HbA1c <7% without 
severe or BG-confirmed symptomatic hypoglycaemia and without weight gain) was achieved 
by nearly half of subjects in the semaglutide 0·5 mg group and nearly two-thirds in the 
semaglutide 1·0 mg group versus less than one-fifth in the insulin glargine group. The 
combination of glycaemic control and body weight reduction with a low potential for 
hypoglycaemia, delivered with a once-weekly injection, is a promising finding given that a 
high proportion of patients with diabetes are overweight/obese and many other treatments 
are either weight-neutral or associated with weight gain accompanied by hypoglycaemia 
and/or the need to be injected daily.2,23  
No new safety issues were identified for semaglutide, and its safety profile seems 
comparable to that of other GLP-1RAs. As expected for a therapy with a glucose-dependent 
mechanism of action, hypoglycaemia incidence in the semaglutide arms was lower than in 
the insulin glargine group, consistent with previous findings both for once-daily15 and once-
weekly24 GLP-1RAs. Furthermore, the majority of hypoglycaemic events observed were 
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reported in subjects receiving sulphonylureas in addition to metformin, indicating  that the 
background therapy has contributed to these events.4 
A comparable proportion of subjects reported SAEs across all three treatment groups. As 
was previously observed with other GLP-1RAs, the main GI side effects reported in the 
semaglutide groups were nausea and diarrhoea. As has been observed with other GLP-
1RAs, GI AE profiles with semaglutide were higher than with insulin glargine, and their 
frequency diminished over time, as has been seen with liraglutide.15,25 Premature treatment 
discontinuation was more frequent with semaglutide, driven primarily by these GI events.  
Dose escalation has been shown to partially ameliorate such AEs.6,9,11 Rates of diarrhoea in 
the current trial were higher than have been previously reported for liraglutide25 or 
exenatide.16 There was also an increase in heart rate in the semaglutide arms and a 
reduction in systolic BP, consistent with previous trials of other long-acting GLP-1RAs.6  Both 
liraglutide (LEADER trial) and semaglutide (SUSTAIN 6 trial) have recently been shown to 
reduce cardiovascular risk.26,27 One potential mechanism may relate to modification of the 
progression of atherosclerosis; the contribution of cardiovascular risk factors to this 
outcome requires further research.26,27 
The rate of pancreatitis in the trial was low, with two events being reported. Although acute 
pancreatitis has been reported following treatment with GLP-1RAs, a causal link has not 
been demonstrated.28 Lipase and amylase levels increased with semaglutide, with a similar 
magnitude compared with other GLP-1RAs.29  In the SUSTAIN 6 trial, no elevated rates of 
acute pancreatitis with semaglutide compared with placebo were seen despite higher lipase 
and amylase levels.27 The rate of cholelithiasis in the current trial was also low, with only 
three cases reported.  
The trial population was heterogeneous, encompassing a broad range in terms of age, 
duration of diabetes and level of HbA1c control at baseline. The population was also 
ethnically diverse compared with other phase 3a programmes in T2D (77% of subjects were 
White, 11% Asian and 9% Black or African American).  
The limitations of this trial included the open-label design, which was due to the different 
dosing frequency and titration of glargine compared with semaglutide. This should be 
especially considered when interpreting endpoints that are prone to subjectivity, such as GI 
AEs and the PROs, in quality of life in the current trial, although the reduced frequency of 
dosing with semaglutide may improve both adherence and quality of life compared with 
once-daily treatments and is perceived to do so by patients.6,7 The trial duration was short, 
Page 16 of 32 
 
limiting the conclusions that can be drawn regarding the long-term efficacy and tolerability 
of semaglutide compared with insulin glargine. In addition, real-world patient populations 
may be expected to have received multiple oral antidiabetic therapies before being 
considered for insulin treatment. Research in populations with longer baseline diabetes 
duration and a longer history of treatment may therefore be of relevance. 
Another limitation of the current trial was the extent to which insulin glargine was titrated. 
All insulin adjustments were at the discretion of the investigators and were not reinforced by 
a titration committee. The mean pre-breakfast fasting SMPG at week 30 (7·1 mmol/L) 
suggests that a more rigorous titration could have been enforced, but that may possibly 
have come at the expense of more hypoglycaemia and body weight gain. Many patients 
may have found it challenging to achieve an SMPG level below 5.5 mmol/l. The overall 
mean insulin dose reported here was in line with that reported in trials comparing other 
weekly GLP-1RAs and insulin glargine,17,22 and the insulin dose at the end of the trial (29·2 
IU/day at 30 weeks) appears to be consistent with clinical practice. It is possible that more 
frequent titrations or discontinuations of sulphonylureas would have allowed more 
aggressive insulin titration.  
In summary, semaglutide was associated with superior glycaemic control and reduced body 
weight, with low hypoglycaemia rates, compared with insulin glargine in patients with T2D 
receiving metformin with or without sulphonylureas. However, it should be noted that 
insulin glargine did not achieve titration targets, reflecting a potential limitation of titration 
often observed in clinical practice. No unexpected safety issues were identified and 
semaglutide showed a similar safety profile to that of other GLP-1RAs. Combined with its 
cardiovascular risk reduction effect recently noted in the SUSTAIN 6 trial, semaglutide 
appears to be an effective once-weekly therapeutic option for patients with T2D who are 
unable to achieve glycaemic control on metformin with or without sulphonylureas. 
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Figures 
Figure 1. Participant flow 
 
 
  
1610 subjects assessed 
for eligibility
1089 enrolled
521 ineligible
Didn’t meet inclusion criteria or 
met exclusion criteria (n=429)
Other (n=29)
1089 randomised
365 assigned IGlar
Exposed (n=360)
26 discontinued treatment
5 [AE]*
1 [pregnancy]
2 randomised in error
18 other
(20 withdrew from trial)
2 withdrew after treatment 
completion
343 trial completed
334 treatment completed
323 treatment completed 
without rescue 
medication
362 assigned 
semaglutide 1·0 mg
Exposed (n=360)
342 trial completed
305 treatment completed
296 treatment completed 
without rescue 
medication
55 discontinued treatment
27 [AE]*
1 [pregnancy]
13 randomised in error
14 other
(19 withdrew from trial)
1 withdrew after treatment 
completion
362 assigned 
semaglutide 0·5 mg
Exposed (n=362)
335 trial completed
313 treatment completed
299 treatment completed 
without rescue 
medication
49 discontinued treatment
9 [AE]*
12 randomised in error
18 other
(24 withdrew from trial)
3 withdrew after treatment 
completion
Subjects completing the trial are defined as those with a follow-up visit. Reasons for subjects not exposed to 
treatment were withdrawal by the subject or loss to follow-up
*Reflects primary reason for treatment discontinuation, as judged by the investigator
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Figure 2. Semaglutide 0·5 mg and 1·0 mg once weekly, compared with insulin glargine: 
change in mean HbA1c by week (A), mean HbA1c after 30 weeks (B), overall mean 
fasting plasma glucose over time (C), mean fasting plasma glucose after 30 weeks (D), 
change in mean body weight by week (E), mean body weight after 30 weeks (F) and 
mean 8-point SMPG profile at baseline and week 30 (G) 
 
 
  
*Indicates significance (p-value <0·0001). Values are estimated means (+/- standard errors) from a mixed model for repeated measurements analysis using 
‘on-treatment without rescue medication’ data from subjects in the full analysis set. Dotted line is the overall mean value at baseline. IGlar, insulin glargine; 
ETD, estimated treatment difference.
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Figure 3. Time course of nausea (A) and diarrhoea (B)  
*Indicates significance (p-value <0·0001). Values are estimated means (+/- standard errors) from a mixed model for repeated measurements analysis using 
‘on-treatment without rescue medication’ data from subjects in the full analysis set. Dotted line is the overall mean value at baseline. IGlar, insulin glargine; 
ETD, estimated treatment difference.
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Treatment-emergent AEs by week. IGlar, insulin glargine. 
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Table 1. Baseline characteristics of trial populations 
 
Semaglutide 0·5 mg Semaglutide 1·0 mg Insulin glargine Total 
 N=362 N=360 N=360 N=1082 
Age* years, mean (SD) 56·5 (10·3) 56·7 (10·4) 56·2 (10·6) 56·5 (10·4) 
Sex, n (%)     
  Female 165 (45·6)  178 (49·4) 165 (45·8) 508 (47·0) 
  Male 197 (54·4)  182 (50·6) 195 (54·2) 574 (53·0) 
HbA1c,
* %, mean (SD) 8·1 (0·85) 8·3 (0·94) 8·1 (0·88) 8·2 (0·89) 
HbA1c,
* mmol/mol, mean (SD) 65·4 (9·28) 66·6 (10·30) 65·4 (9·58) 65·8 (9·74) 
Diabetes duration,* years,  
mean (SD) 
7·8 (5·14) 9·3 (7·17) 8·6 (6·29) 8·6 (6·28) 
Body weight,* mean, kg (SD) 93·7 (21·39) 94·0 (22·48) 92·6 (21·52) 93·5 (21·79) 
BMI,* kg/m2, mean (SD) 33·1 (6·45) 33·0 (6·51) 33·0 (6·51) 33·0 (6·49) 
eGFR (MDRD),* mL/min/1·73 
m2, mean (SD) 
97·9 (25·94) 98·0 (27·55) 99·7 (26·46) 98·5 (26·64) 
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Oral antidiabetes treatment, n 
(%)† 
    
  Metformin monotherapy 176 (48·6)  175 (48·6) 172 (47·8) 523 (48·3) 
  Metformin + SU 186 (51·4)  185 (51·4) 188 (52·2) 559 (51·7) 
Ethnicity, n(%)     
  Hispanic or Latino 61 (16·9) 74 (20·6) 78 (21·7) 213 (19·7) 
  Not Hispanic or Latino 301 (83·1)  286 (79·4) 281 (78·1) 868 (80·2) 
  NA‡ 0 0 1 (0·3) 1 (0·1) 
Race, n(%)     
    American Indian or Alaska 
Native 
1 (0·3) 0 (0·0) 1 (0·3) 2 (0·2) 
    Asian 42 (11·6) 39 (10·8) 38 (10·6) 119 (11·0) 
    Black or African American 32 (8·8) 34 (9·4) 33 (9·2) 99 (9·1) 
    White 279 (77·1) 279 (77·5) 276 (76·7) 834 (77·1) 
    Other 3 (0·8) 3 (0·8) 5 (1·4) 11 (1·0) 
    NA‡ 5 (1·4) 5 (1·4) 7 (1·9) 17 (1·6) 
*Values are means; †Metformin doses ≥1500 mg or maximum tolerated dose were allowed. SU doses ≥half of maximum dose allowed according to national label; ‡One subject in US 
site chose not to report ethnicity, and race was not collected in France sites (all counted as NA). BMI, body mass index; eGFR, estimated glomerular filtration rate; MDRD, Modification 
of Diet in Renal Disease; SD, standard deviation; SU, sulphonylurea 
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Table 2. Primary and selected secondary endpoints by treatment group 
 Overall 
baseline, 
mean 
[SD] 
 Semaglutide 
0·5 mg 
  Semaglutide  
1·0 mg 
 Insulin 
glargine 
  Change 
from 
baseline at 
Week 30 
Mean [SE] 
ETD 
[95% CI] 
p Change 
from 
baseline at  
Week 30 
Mean [SE] 
ETD 
[95% CI] 
p Change from 
baseline at 
Week 30 
 
Mean [SE] 
Glycaemia endpoints 
HbA1c (%) 8·2 
[0·89] 
–1·2 
[0·05] 
–0·38 
[–0·52; –0·24] 
<0·0001 –1·6 
[0·05] 
–0·81 
[–0·96; –0·67] 
<0·0001 –0·8 
[0·05] 
HbA1c (mmol/mol) 65·8 
[9·74] 
–13·2 
[0·57] 
–4·16 
[–5·72; –2·60] 
<0·0001 –17·9 
[0·58] 
–8·87 
[–10·45; –7·30] 
<0·0001 –9·1 
[0·55] 
FPG (mmol/L) 9·7 
[2·84] 
–2·0 
[0·12] 
0·08 
[–0·24; 0·40] 
0·6243 –2·7 
[0·12] 
–0·61 
[–0·93; –0·29] 
0·0002 –2·1 
[0·11] 
8-point SMPG (mmol/L)         
   Mean 
 
10·9 
[2·54] 
–2·4 
[0·10] 
–0·04 
[–0·30; 0·23] 
0·7816 –2·9 
[0·10] 
–0·57 
[-0·83; -0·31] 
<0·0001 –2·4 
[0·09] 
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   Increment 2·4 
[1·95] 
–0·6 
[0·09] 
–0·39 
[–0·65; –0·13] 
0·0029 –0·9 
[0·10] 
–0·65 
[–0·91; –0·39] 
<0·0001 –0·2 
[0·09] 
Body weight endpoints 
Body weight (kg) 93·5 
[21·79] 
–3·5 
[0·24] 
–4·62 
[–5·27; –3·96] 
<0·0001 –5·2 
[0·24] 
–6·33 
[–6·99; –5·67] 
<0·0001 1·2 
[0·23] 
BMI (kg/m2) 33·0 
[6·49] 
–1·2 
[0·08] 
–1·66 
[–1·89; –1·43] 
<0·0001 –1·9 
[0·09] 
–2·27 
[–2·51; –2·04] 
<0·0001 0·4 
[0·08] 
Waist circumference (cm) 109·2 
[15·16] 
–3·2 
[0·30] 
–3·42 
[–4·24; –2·59] 
<0·0001 –4·5 
[0·31] 
–4·76 
[–5·59; –3·93] 
<0·0001 0·2 
[0·29] 
Blood pressure and pulse rate 
DBP (mmHg) 79·9 
[8·53] 
–1·4 
[0·43] 
0·06 
[–1·12; 1·24] 
0·9183 –1·0 
[0·44] 
0·45 
[–0·74; 1·64] 
0·4545 –1·4 
[0·41] 
SBP (mmHg) 132·1 
[15·31] 
–4·6 
[0·72] 
–2·97 
[–4·92; –1·03] 
0·0028 –5·2 
[0·73] 
–3·50 
[–5·46; –1·54] 
0·0005 –1·7 
[0·68] 
Pulse rate (bpm) 74.5  
[10.22] 
2.3 
[0.47] 
2.36 
[1.07; 3.65] 
0.0004 3.1 
[0.48] 
3.19 
[1.88; 4.50] 
<0·0001 <–0.1 
[0.46] 
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Treatment targets 
  Semaglutide 
0·5 mg 
  Semaglutide  
1·0 mg 
 Insulin 
glargine 
 Subjects 
achieving 
target,  
n (%) 
OR 
[95% CI] 
p Subjects 
achieving 
target,  
n  (%) 
OR 
[95% CI] 
p Subjects 
achieving 
target,  
n (%) 
Proportion achieving HbA1c  
targets 
       
   <7·0% (<53 mmol/mol) 208 (57·5)         2·39 
[1·73; 3·28]  
<0·0001 264 (73·3) 5·78 
[4·08; 8·19] 
<0·0001 137 (38·1) 
   ≤6·5% (≤48 mmol/mol) 135 (37·3) 3·02 
[2·11; 4·33] 
<0·0001 195 (54·2) 6·86 
[4·76; 9·89] 
<0·0001 63 (17·5) 
Proportion achieving body weight 
reduction 
       
   ≥5% 134 (37·0) 13·37 
[7·71; 23·20] 
<0·0001 183 (50·8) 23·94 
[13·80; 41·50] 
<0·0001 17 (4·2) 
   ≥10% 28 (7·5) 6·35 
[2·42; 16·69] 
0·0002 57 (15·8) 14·51 
[5·70; 36·92] 
<0·0001 6 (1·1) 
Proportion achieving HbA1c <7·0% 
without severe or BG–confirmed 
hypoglycaemia and without weight 
gain 
169 (46·7) 5·39 
[3·72; 7·81] 
<0·0001 231 (64·2) 12·88 
[8·73; 19·02] 
<0·0001 56 (15.6) 
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Odds ratios are calculated from logistic regression models adjusted for treatment, country, stratification and baseline HbA1c. * baseline is for the entire trial population; † missing 
body weight data imputed by MMRM; p-value is for a two-sided test of the null hypothesis that there is no difference. BMI, body mass index; BP, blood pressure; CI, confidence 
interval; FPG, fasting plasma glucose; SE, standard error; SMPG, self-monitored plasma glucose 
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Table 3. Adverse events overview 
 
Semaglutide 0·5 mg Semaglutide 1·0 mg IGlar 
N (%) E N (%) E N (%) E 
Number of subjects 362 - - 360 - - 360 - - 
Serious adverse events 22 6·1 31 17 4·7 23 18 5·0 21 
Fatal 4 1·1 4 0 - - 2 0·6 2 
Any adverse events 253 69·9 1026 264 73·3 1151 235 65·3 743 
Severe 27 7·5 48 20 5·6 33 10 2·8 12 
Moderate 108 29·8 201 110 30·6 233 104 28·9 196 
Mild 221 61·0 777 230 63·9 885 193 53·6 535 
GI adverse events 149 41.2 345 156 43.3 525 54 15.0 91 
Severe 7 1·9 10 6 1·7 11 2 0·6 2 
Moderate 36 9·9 49 51 14·2 90 15 4·2 17 
Mild 132 36·5 286 137 38·1 424 44 12·2 72 
Adverse events leading to premature treatment 
discontinuation 
20 5·5 29 27 7·5 45 4 1·1 5 
   All GI adverse events 11 3·0 15 19 5·3 31 0 - - 
     Nausea 3 0·8 3 7 1·9 7 0 - - 
     Vomiting 3 0·8 3 7 1·9 7 0 - - 
     Diarrhoea 1 0·3 1 9 2·5 9 0 - - 
Adverse events by preferred term (≥5% of 
subjects) 
         
Nausea 77 21·3 101 80 22·2 117 13 3·6 16 
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Diarrhoea 59 16·3 67 69 19·2 118 16 4·4 18 
Nasopharyngitis 45 12·4 58 29 8·1 37 44 12·2 51 
Lipase increased 36 9·9 39 30 8·3 32 15 4·2 17 
Decreased appetite 25 6·9 34 23 6·4 23 1 0·3 1 
Vomiting 24 6·6 28 37 10·3 119 11 3·1 13 
Headache 19 5·2 40 23 6·4 33 20 5·6 26 
Dyspepsia 12 3·3 24 24 6·7 39 2 0·6 2 
Back pain 11 3 11 18 5 20 7 1·9 10 
Upper respiratory tract infection 10 2·8 10 14 3·9 16 24 6·7 25 
Gastro-oesophageal reflux disease 4 1·1 4 19 5·3 20 3 0·8 4 
Other adverse events          
Pancreatitis 2 0·6 2 0 - - 0 - - 
Cholelithiasis 1 0·3 1 2 0·6 2 0 - - 
Cardiovascular 3 0.8 3 3 0.8 4 4 1.1 4 
Malignant neoplasms 4 1·1 4 0 - - 1 0·3 1 
Skin 1 0·3 1 0 - - 1 0.3 1 
Naso-pharyngeal 1 0·3 1 0 - -    
Pancreatic 1 0·3 1 0 - 0 0 - - 
Renal/adrenal 1 0·3 1 0 - - 0 - - 
   Benign neoplasms 5 1·4 5 2 0·6 4 3 0·8 4 
Summary of treatment-emergent AEs includes events that are collected from first exposure to the follow-up visit scheduled 5 weeks (+1 week visit window) after last trial product 
dose. E, number of events; N, number of subjects.. The 5% is calculated based on the total number of subjects in the safety analysis set 
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